Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab and PD-1 Blockade Strategy in R/R Hodgkin Lymphoma
NCT05595447Phase 3Recruiting
- Sponsor
- Hospital Regional de Alta Especialidad del Bajío
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of brentuximab vedotin, nivolumab, pembrolizumab in Hodgkin lymphoma (HL), sponsored by Hospital Regional de Alta Especialidad del Bajío. Started Oct 2022; status: recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT05595447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595447.